A First-in-Human Study of ABBV-525 (MALT1 Inhibitor) in B-Cell Malignancies

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2022-503136-13-00

Acronym

M23-324

Enrollment

Registered

2023-10-17

Start date

2024-02-29

Completion date

Unknown

Last updated

2025-10-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

various B-cell malignancies

None listed

Sex/Gender

All

Age

18 Years to No maximum

Belgium, France, Germany, Spain

None listed

Source: EU CTIS · Data processed: Feb 4, 2026